Neuroscience
Neuropsychopharmacology
Recently the focus of Valtorta’s lab has shifted from the physiological mechanisms underlying synaptic development and function to the mechanisms through which mutations in genes coding for synaptic proteins lead to neurological or psychiatric disorders.
Synaptic dysfunction is an early event also in diseases previously thought to be essentially neurodegenerative or neuroinflammatory (e.g. Parkinson disease and multiple sclerosis), thus the unit is extending research to these disorders, in the belief that a better understanding of synaptic physiology and of its derangements in synaptopathies may offer novel clues for the development of therapeutic strategies.
Recent new lines of research in the group concern the molecular bases of mood disorders and drug addiction, with a focus on serotonin and on the potential therapeutic role of psychedelics.
Research activity
Pathogenic mechanisms of synaptopathies (Flavia Valtorta)
We have significantly contributed to the elucidation of the role of synaptic vesicle proteins in neurotransmitter release and synaptic plasticity. We have also shown that genetically altered mice lacking selected synaptic proteins develop neurological or psychiatric disorders. We are using these mice as models of human diseases, in the search for an informed approach to the development of more effective therapies.
Early events in neurodegenerative disorders (Jenny Sassone)
We aim at understanding the molecular mechanisms underlying synaptic dysfunction in neurodegenerative diseases characterized by movement disorders. The ultimate goal is to halt or reverse neurodegeneration through neuroprotective strategies.
Molecular mechanisms underlying drug addiction (Danilo De Gregorio)
Psychoactive drugs alter brain function, influencing thoughts, actions, and emotions. Each drug carries unique risks, but common ones include addiction and exacerbation of mental illness symptoms. Using a combination of behavioral assays and electrophysiology in rodents, our goal is to comprehend how these drugs affect behavior.
Involvement of the serotonin and melatonin systems in mood disorders (Stefano Comai)
We aim at determining the extent to which the metabolically connected systems of serotonin and melatonin are involved in the etiology of mood disorders. The ultimate goal is to increase our understanding of the pathophysiological mechanisms of mood disorders, and with this knowledge develop new pharmacologically active compounds.
